ThromboGenics NV Successfully Introduces New 'Already-Diluted' Formulation Of JETREA (Ocriplasmin) In The U.S.
Published: Sep 28, 2017
Leuven, Belgium, 28th September, 2017 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for retinal disorders, with a focus on diabetic eye disease, today announced that it has successfully introduced a new 'Already-Diluted' formulation of JETREA® in the US. The new formulation is designed to eliminate the preparatory dilution steps before injection. At the point of administration into the eye, the strength, potency, composition and pharmaceutical form of the already-diluted formulation remain identical to the currently available formulation after dilution.
JETREA® is the first and only pharmacological treatment for symptomatic vitreomacular adhesion (VMA) in the US and vitreomacular traction (VMT) in Europe and elsewhere in the world. VMA and VMT are age-related progressive, sight-threatening conditions that may lead to visual distortion, decreased visual acuity and central blindness. It has been approved in 54 countries worldwide. The product which was first introduced in 2013 has so far been used to treat close to 30,000 patients globally.
ThromboGenics is commercializing JETREA® via its subsidiary ThromboGenics, Inc. in the US.
More information on the new Already Diluted JETREA® can be found at www.jetrea.com.
Dr. Patrik De Haes, CEO of ThromboGenics nv, said "We are delighted to launch this new 'already-diluted' formulation of JETREA®, which has been developed to meet physicians' needs. With this new formulation, it will be easier and more convenient for retina physicians to use this novel pharmacological option for the treatment of patients with symptomatic vitreomacular adhesion (sVMA)."
Last week, ThromboGenics announced that it regained the full global rights to JETREA® from Alcon, a Novartis company, based on a mutual agreement that the unique characteristics of JETREA make Thrombogenics a better fit for building a sustainable long-term business. Under the terms of the agreement, ThromboGenics received a cash amount of €53.7 million and a forthcoming Novartis equity investment of €10 million in ThromboGenics capital.
Following the agreements with Alcon/Novartis, ThromboGenics has over €120 million in cash, which will be used to progress its pipeline of novel and unique disease modifying medicines for the treatment of diabetic eye disease.
- END -
For further information please contact:
Global Head of Corp Coms & Investor Relations
+32 16 75 13 10 / +32 478 33 56 32
| Citigate Dewe Rogerson|
David Dible/ Sylvie Berrebi/ Isabelle Andrews
Tel: +44 20 7282 9571
ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for eye disease, with a focus on diabetic eye disease. The company's pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.
ThromboGenics is conducting a Phase IIa clinical trial evaluating multiple doses of THR-409 (ocriplasmin) to induce a total Posterior Vitreous Detachment in patients with Non-Proliferative Diabetic Retinopathy (NPDR).
ThromboGenics is conducting a Phase II clinical study evaluating THR- 317, a PLGF inhibitor for the treatment of diabetic macular edema, as a stand-alone or as a combination therapy with anti-VEGF treatments. In addition, THR-149, a plasma kallikrein inhibitor, which has resulted from research collaboration with Bicycle Therapeutics, and THR-687, an integrin antagonist, which was in-licensed from Galapagos, are in late stage pre-clinical development.
ThromboGenics pioneered a new drug category of pharmacological vitreolysis with JETREA® (ocriplasmin) which is now approved for the treatment of symptomatic vitreomacular traction in 54 countries worldwide.
ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.
This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.